Hemodynamic effects of combined treatment with @entity3303 , XXXX and @entity6310 in acute @entity583 .

@entity1 @entity64 @entity1165 @entity477 @entity551 @entity591 @entity3303 @entity6310 @entity583 @entity1818 @entity1168
In the treatment of refractory @entity1165 antiarrhythmic drugs must sometimes be combined. An electrophysiologically appropriate combination is @entity3303 and @entity1818 and, when needed, @entity477 -blocking agent. The hemodynamic effects of this treatment were studied in 6 @entity1 in the acute phase of @entity583 . After a control period, an infusion of @entity3303 was started and 1 h later @entity1818 /placebo was added in a double-blind system and finally also @entity6310 /placebo. The drugs were given intravenously in ordinary doses. Hemodynamics were studied by bedside catheterization. During triple treatment heart rate and aortic pressures fell significantly whereas right atrial mean pressure increased compared to the control period. @entity64 volume, cardiac output and pulmonary artery pressures were unchanged. Most of the changes appeared when @entity6310 was added. Following the @entity1818 injection a transient fall in aortic pressures was noted. @entity3303 gave no hemodynamic effects. The number of ventricular premature beats was reduced in all @entity1 and no @entity1 had @entity1165 during treatment. In these @entity1 it was possible to combine @entity3303 , @entity1818 and @entity6310 in the acute phase of @entity583 . However, 3 @entity1 developed @entity551 , 1 sinus @entity1168 and 1 had a short run of @entity591 . It is concluded that this kind of combined treatment, because of its potential risks, should be restricted to critical clinical situations and then it ought to be hemodynamically controlled.
